- Home
- ZAPP vs WINT Comparison
ZAPP vs WINT Comparison
Compare ZAPP & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZAPP
- WINT
- Stock Information
- Founded
- ZAPP 2017
- WINT 1992
- Country
- ZAPP Thailand
- WINT United States
- Employees
- ZAPP N/A
- WINT N/A
- Industry
- ZAPP Motor Vehicles
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZAPP Consumer Discretionary
- WINT Health Care
- Exchange
- ZAPP Nasdaq
- WINT Nasdaq
- Market Cap
- ZAPP 13.5M
- WINT 1.8M
- IPO Year
- ZAPP N/A
- WINT 1995
- Fundamental
- Price
- ZAPP $2.70
- WINT $0.99
- Analyst Decision
- ZAPP
- WINT Hold
- Analyst Count
- ZAPP 0
- WINT 1
- Target Price
- ZAPP N/A
- WINT $18.00
- AVG Volume (30 Days)
- ZAPP 87.7K
- WINT 1.7M
- Earning Date
- ZAPP 11-01-2024
- WINT 11-07-2024
- Dividend Yield
- ZAPP N/A
- WINT N/A
- EPS Growth
- ZAPP N/A
- WINT N/A
- EPS
- ZAPP N/A
- WINT N/A
- Revenue
- ZAPP N/A
- WINT N/A
- Revenue This Year
- ZAPP N/A
- WINT N/A
- Revenue Next Year
- ZAPP $41,300.00
- WINT N/A
- P/E Ratio
- ZAPP N/A
- WINT N/A
- Revenue Growth
- ZAPP N/A
- WINT N/A
- 52 Week Low
- ZAPP $0.70
- WINT $0.66
- 52 Week High
- ZAPP $19.10
- WINT $23.58
- Technical
- Relative Strength Index (RSI)
- ZAPP 38.70
- WINT 29.67
- Support Level
- ZAPP $2.56
- WINT $1.04
- Resistance Level
- ZAPP $2.86
- WINT $0.76
- Average True Range (ATR)
- ZAPP 0.18
- WINT 0.18
- MACD
- ZAPP 0.09
- WINT 0.13
- Stochastic Oscillator
- ZAPP 22.05
- WINT 17.28
About ZAPP Zapp Electric Vehicles Group Limited
Zapp Electric Vehicles Group Ltd designs manufactures, and sells high-performance electric vehicles, including maintenance and repair of electric vehicles and related parts and accessories.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.